The Medicines Company (MDCO) : Zacks Investment Research ranks The Medicines Company (MDCO) as 4, which is a Sell recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 8 research analysts is 1.13, which indicates as a Strong Buy.
The Medicines Company (MDCO) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $65 and the lowest price target forecast is $41. The average forecast of all the analysts is $49.29 and the expected standard deviation is $8.22.
The Medicines Company (NASDAQ:MDCO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $33.55 and $33.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $34.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $34.91, notching a gain of 3.78% for the day. The total traded volume was 1,345,321 . The stock had closed at $33.64 on the previous day.
Also, Cowen & Company initiates coverage on The Medicines Company (NASDAQ:MDCO) The brokerage firm has issued a Outperform rating on the shares. The rating by the firm was issued on May 5, 2016. The company shares have rallied 3.80% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $43.79 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $35.95 and the 200 Day Moving Average price is recorded at $34.15.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.